《中国肝病诊疗管理规范》白皮书(节选)

doi:10.3969/j.issn.1001-5256.2014.03.002

《中国肝病诊疗管理规范》白皮书(节选)

DOI: 10.3969/j.issn.1001-5256.2014.03.002

基金项目:

中国医院协会鲲鹏项目；

详细信息

中图分类号: R575.2
计量
- 文章访问数: 207
- HTML全文浏览量: 18
- PDF下载量: 1289
- 被引次数: 0
出版历程
- 出版日期: 2014-03-20

Chinese standards for diagnosis and treatment of liver disease-White paper excerpt

Research funding:

摘要

摘要:
<正>(编者按:本文刊载的内容为63名专家编写的《中国肝病诊疗管理规范》白皮书的绪论和第二卷)绪论 1肝脏病学简介人类对肝脏和肝脏疾病的认识有着非常悠久的历史,早在公元前2000年的古巴比伦时代,就出现了用陶土制作的动物肝脏模型。公元前400年人们已经对肝脏疾病有了一定的认识,当时古希腊名医希波克拉底(Hippocrates,公元前460~377年)提到了肝脓肿,公元100年土耳其卡帕多细亚医生Areteus认识到了黄疸。古罗马解剖学家盖伦(Galen,公元130~200年)描述了肝脏与胆囊和脾脏的关系。中世纪欧洲(1316年)
- 肝疾病 /
- 诊断 /
- 治疗学 /
- 指南
- liver diseases /
- diagnosis /
- therapeutics /
- guidebooks

HTML全文

参考文献(43)

[1]LIANG X, BI S, YANG W, et al.Epidemiological serosurvey of hepatitis B in China-declining HBV prevalence due to hepatitis B vaccination[J].Vaccine, 2009, 27 (47) :6550-6557.

[2]MAST EE, WEINBAUM CM, FIORE AE, et al.A comprehensive immunization strategy to eliminate transmission of hepatitis B virus infection in the United States:recommendations of the Advisory Committee on Immunization Practices (ACIP) Part II:immunization of adults[J].MMWR Re-comm Rep, 2006, 55 (RR-16) :1-33, E1-4.

[3] 中华医学会肝病学分会, 中华医学会感染病学分会.慢性乙型肝炎防治指南 (2010版) [J].中国病毒病杂志, 2011, 1 (1) :9-23.

[4]崔富强, 王富珍, 吴振华, 等.中国2005~2010年报告乙型病毒性肝炎发病分析[J].中国疫苗和免疫, 2011, 17 (6) :483-486.

[5] 王贵强, 贾继东, 庄辉, 等.卫生部《乙型肝炎诊断标准》.2008.

[1] GANEM D, PRINCE AM.Hepatitis B virus infection natural history and clinical consequences[J].N Engl J Med, 2004, 350 (11) :1118-1129.

[2]WORLD HEALTH ORGANIZATION.Hepatitis B. (Revised August 2008) .http://www.who.int/mediacen-tre/factsheets/fs204/en/[2010-12-9].

[3] LIANG X, BI S, YANG W, et al.Epidemiological serosurvey of hepatitis B in China-declining HBV prevalence due to hepatitis B vaccination[J].Vaccine, 2009, 27 (47) :6550-6557.

[4] LIANG X, BI S, YANG W, et al.Evaluation of the impact of hepatitis B vaccination among children born during 1992-2005 in China[J].J Infect Dis, 2009, 200 (1) :39-47.

[5] LU FM, ZHUANG H.Management of hepatitis B in China[J].Chin Med J (Engl) , 2009, 122 (1) :3-4.

[6] CHAN HL, LEUNG NW, HUI AY, et al.A randomized controlled trial of combination therapy for chronic hepatitis B:comparing pegylated interferon-alpha2b and lamivudine with lamivudine alone[J].Ann Intern Med, 2005, 142 (4) :240-250.

[7]乙型肝炎病毒耐药专家委员会.乙型肝炎病毒耐药专家共识[J/CD].中华实验和临床感染病杂志:电子版, 2008, 2 (1) :90-98.

[8]乙型肝炎病毒耐药专家委员会.乙型肝炎病毒耐药专家共识:2009年更新[J/CD].中华实验和临床感染病杂志:电子版, 2009, 3 (1) :72-79.

[9]KEEFFE EB, DIETERICH DT, PAWLOTSKY JM, et al.Chronic hepatitis B:preventing, detecting, and managing viral resistance[J].Clin Gastroenterol Hepatol, 2008, 6 (3) :268-274.

[10]SUN J, YUAN Q, XIE Q, et al.Baseline quantitative hepatitis B core antibody is the strongest pre-dictor for 2-year HBeAg seroconversion in HBeAg positive CHB patients treated with telbivudine alone or combined with Adefovir[J].Hepatology, 58 (4) (Suppl) :701A.

[1]CHU CM, LIAW YF.Hepatitis B virus-related cirrhosis:natural history and treatment[J].Semin Liver Dis, 2006, 26 (2) :142-152.

[2]FATTOVICH G, PANTALENA M, ZAGNI I, et al.Effect of hepatitis B and C virus infections on the natural history of compensated cirrhosis:a cohort study of 297 patients[J].Am J Gastroenterol, 2002, 97 (11) :2886-2895.

[3] LIAW YF, SUNG JJ, CHOW WC, et al.Lamivudine for patients with chronic hepatitis B and ad-vanced liver disease[J].N Engl J Med, 2004, 351 (15) :1521-1531.

[4]IKEDA K, SAITOH S, SUZUKI Y, et al.Interferon decreases hepatocellular carcinogenesis in patients with cirrhosis caused by the hepatitis B virus:a pilot study[J].Cancer, 1998, 82 (5) :827-835.

[5]CHIARAMONTE M, STROFFOLINI T, VIAN A, et al.Rate of incidence of hepatocellular carcinoma in patients with compensated viral cirrhosis[J].Cancer, 1999, 85 (10) :2132-2137.

[6]DI MARCO V, LO LACONO O, CAMMC, et al.The longterm course of chronic hepatitis B[J].Hepatology, 1999, 30 (1) :257-264.

[7]SCHUPPAN D, AFDHAL NH.Liver cirrhosis[J].Lancet, 2008, 371 (9615) :838-851.

[8]BRCHOT C.Pathogenesis of hepatitis B virus-related hepatocellular carcinoma:old and new paradigms[J].Gastroenterology, 2004, 127 (5 Suppl 1) :s56-s61.

[9]姚光弼.临床肝脏病学[M].上海:上海科学技术出版社, 2004.

[10]CASTERA L.Noninvasive methods to assess liver disease in patients with hepatitis B or C[J].Gastroenterology, 2012, 142 (6) :1293-1302.

[1]ROUSSOS A, KOILAKOU S, KALAFATAS I, et al.Lamivudine treatmentforacute severe hepatitm B:report of a case and review of theliterature[J].Acta Gastroenterol Belg, 2008, 71 (1) :30-32.

[2]TILLMANNHL, HARLEM J, LEIFELD L, et al.Safety and efficacy of lamivudine in patients with severe acute or fulminant hepatitis B, a multi-center experience[J].J Viral Hepat, 2006, 13 (4) :256-263.

[3]王融冰, 周桂琴, 江宇泳, 等.799例重型肝炎患者的临床病原学与实验室分析[J].中华肝脏病杂志, 2006, 14 (9) :655-657.

[4] WONG VW, WONG GL, TSANG SW, et al.Long-term follow-up of1amivudine treatment in pa-tients with severeacute exacerbation of hepatitis B e antigen (HBeAg) -positive chronic hepatitis B[J].Antivir Ther, 2008, 13 (4) :571-579.

[5] PAPATHEODORIDIS GV, CHOLONGITAS E, ARCHIMANDRITIS AJ, et al.Current management of hepatitis B virus infection before and after liver transplantation[J].Liver Int, 2009, 29 (9) :1294-1305.

[6]GRELLIER L, MUTIMER D, AHMED M, et al.Lamivudine prophylaxis against reinfection in liver transplantation forhepatitis B cirrhosis[J].Lancet, 1996, 348:1212-1215.

[7]SAMUEL D.Management of hepatitis B in liver transplantation patients[J].Semin Liver Dis, 2004, 24:55-62.

[8] SCHIFF E, LAI CL, HADZIYANNIS S, et al.Adefovir dipivoxil for wait-listed and post-liver trans-plantation patientswith lamivudine-resistant hepatitis B:final long-term results[J].Liver Transpl, 2007, 13 (3) :349-360.

[9]LOOMBA R, ROWLEY AK, WESLEY R, et al.Hepatitis B immunoglobulin and lamivudine improve hepatitis B-relaated outcomes after liver transplantation:meta-analysis[J].Clin Gastroenterol Hepatol, 2008, 6 (6) :696-700.

[10]FUNG J, CHEUNG C, CHAN SC, et al.Entecavir monotherapy is effective in suppressing hepatitis B virus after liver transplantation[J].Gastroenterology, 2011, 141 (4) :1212-1219.

[1]胡善联.上市后药物的经济学评价[J].中国循证医学, 2005, 5 (5) :353-356.

[2]阎小青.药物经济学研究概述[J].天津药学, 2009, 21 (6) :49-51.

[3] 中国药学会药物经济学专业委员会.中国药物经济学评价指南 (2011版) [J].中国药物经济学, 2011, 3:6-48.

[4]WU B, LI T, CHEN H, et al.Cost-effectiveness of nucleoside analog therapy for hepatitis B in China:a Markov analysis[J].Value in Health, 2010, 13 (5) :592-600.

[5]TOY M, HAO J, VIAS SJ, et al.The burden of chronic hepatitis B and the cost-effectiveness of treating eligible patients in Shanghia-China.2010 AASLD poster:411.

[6]WEI L, HU SL, HOU JL, et al.A novel estimation of the impact of treatment with entecavir on long-term mortality, morbidity and healthcare costs of chronic hepatitis B in China.2012 APASL post-er:9-45.

[7]胡善联.慢性乙肝核苷类抗病毒药物治疗价值评估模型研究[J].中国医疗保险, 2012, 4 (5) :57-58.

[8]WEI L, HU SL, HOU JL, et al.A novel estimation of the impact of treatment with entecavir on long-term mortality, morbidity and healthcare costs of chronic hepatitis B in China[J].Value in Health Regional Issues, 2013, 2 (1) :48-56.

施引文献

资源附件(0)

访问统计